WO2024097284A1 - Mavacamten and derivatives thereof for use in treating atrial dysfunction - Google Patents
Mavacamten and derivatives thereof for use in treating atrial dysfunction Download PDFInfo
- Publication number
- WO2024097284A1 WO2024097284A1 PCT/US2023/036587 US2023036587W WO2024097284A1 WO 2024097284 A1 WO2024097284 A1 WO 2024097284A1 US 2023036587 W US2023036587 W US 2023036587W WO 2024097284 A1 WO2024097284 A1 WO 2024097284A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- compound
- atrial
- optionally
- atrial fibrillation
- Prior art date
Links
- 230000001746 atrial effect Effects 0.000 title claims description 87
- 230000004064 dysfunction Effects 0.000 title claims description 45
- RLCLASQCAPXVLM-NSHDSACASA-N CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O Chemical compound CC(C)n1c(=O)cc(N[C@@H](C)c2ccccc2)[nH]c1=O RLCLASQCAPXVLM-NSHDSACASA-N 0.000 title description 17
- 229940069673 mavacamten Drugs 0.000 title description 17
- 206010003658 Atrial Fibrillation Diseases 0.000 claims abstract description 145
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 79
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 106
- 239000003814 drug Substances 0.000 claims description 38
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical group 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 27
- 229910052731 fluorine Inorganic materials 0.000 claims description 24
- 239000011737 fluorine Substances 0.000 claims description 24
- 230000002829 reductive effect Effects 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 24
- 230000033764 rhythmic process Effects 0.000 claims description 21
- 208000001871 Tachycardia Diseases 0.000 claims description 19
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 17
- 206010049447 Tachyarrhythmia Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 206010019280 Heart failures Diseases 0.000 claims description 13
- 238000013195 electrical cardioversion Methods 0.000 claims description 13
- 230000002861 ventricular Effects 0.000 claims description 13
- 238000013194 cardioversion Methods 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 8
- 230000002459 sustained effect Effects 0.000 claims description 8
- 102100026893 Troponin T, cardiac muscle Human genes 0.000 claims description 7
- 101710165323 Troponin T, cardiac muscle Proteins 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 210000005246 left atrium Anatomy 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000002206 pro-fibrotic effect Effects 0.000 claims description 4
- 206010074269 Tachycardia induced cardiomyopathy Diseases 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 208000005189 Embolism Diseases 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 description 36
- 229940126062 Compound A Drugs 0.000 description 29
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 29
- 239000003146 anticoagulant agent Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 14
- 241000282887 Suidae Species 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 230000000747 cardiac effect Effects 0.000 description 10
- 102000003505 Myosin Human genes 0.000 description 9
- 239000003416 antiarrhythmic agent Substances 0.000 description 9
- 230000000414 obstructive effect Effects 0.000 description 9
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- 239000002876 beta blocker Substances 0.000 description 8
- 229940097320 beta blocking agent Drugs 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000002085 persistent effect Effects 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 6
- 108060008487 Myosin Proteins 0.000 description 6
- 238000002679 ablation Methods 0.000 description 6
- 229960005260 amiodarone Drugs 0.000 description 6
- 206010042772 syncope Diseases 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 208000013220 shortness of breath Diseases 0.000 description 5
- 208000032845 Atrial Remodeling Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229960002994 dofetilide Drugs 0.000 description 4
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 4
- 208000018578 heart valve disease Diseases 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 229940127216 oral anticoagulant drug Drugs 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 3
- 229940127291 Calcium channel antagonist Drugs 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108030001204 Myosin ATPases Proteins 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 239000000480 calcium channel blocker Substances 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 229960001066 disopyramide Drugs 0.000 description 3
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 244000309715 mini pig Species 0.000 description 3
- 210000003365 myofibril Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229960002370 sotalol Drugs 0.000 description 3
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 3
- 230000006794 tachycardia Effects 0.000 description 3
- WBSMIPAMAXNXFS-UHFFFAOYSA-N 5-Nitro-2-(3-phenylpropylamino)benzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC=C1NCCCC1=CC=CC=C1 WBSMIPAMAXNXFS-UHFFFAOYSA-N 0.000 description 2
- 108091006112 ATPases Proteins 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 2
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 2
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 2
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 2
- 208000035211 Heart Murmurs Diseases 0.000 description 2
- 101000928278 Homo sapiens Natriuretic peptides B Proteins 0.000 description 2
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- 102100036836 Natriuretic peptides B Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010036653 Presyncope Diseases 0.000 description 2
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 description 2
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229960004195 carvedilol Drugs 0.000 description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 2
- 238000013153 catheter ablation Methods 0.000 description 2
- 231100000762 chronic effect Toxicity 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 229960002084 dronedarone Drugs 0.000 description 2
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 description 2
- 229960000449 flecainide Drugs 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- -1 glidants Substances 0.000 description 2
- 229960004053 ibutilide Drugs 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002796 non-dihydropyridine calcium channel blocker Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000013310 pig model Methods 0.000 description 2
- 229960000203 propafenone Drugs 0.000 description 2
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 208000004124 rheumatic heart disease Diseases 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010967 transthoracic echocardiography Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 108010051609 Cardiac Myosins Proteins 0.000 description 1
- 102000013602 Cardiac Myosins Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000031976 Channelopathies Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- 206010013971 Dyspnoea exertional Diseases 0.000 description 1
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- RGHAZVBIOOEVQX-UHFFFAOYSA-N Metoprolol succinate Chemical compound OC(=O)CCC(O)=O.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 RGHAZVBIOOEVQX-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
- 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229940125516 allosteric modulator Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 210000002072 atrial myocyte Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960003850 dabigatran Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 229960000622 edoxaban Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 229940100321 entresto Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- ZASXKEGREHRXDL-CAWNUZPDSA-H hexasodium;4-[[(2s,4r)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC([O-])=O)=CC=C1C1=CC=CC=C1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C([O-])=O)=CC=C1C1=CC=CC=C1C1=NN=N[N-]1 ZASXKEGREHRXDL-CAWNUZPDSA-H 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000005248 left atrial appendage Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960000939 metoprolol succinate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 208000030390 pulmonic stenosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 1
- 102200136804 rs121913624 Human genes 0.000 description 1
- PYNXFZCZUAOOQC-UTKZUKDTSA-N sacubitril Chemical compound C1=CC(C[C@H](C[C@@H](C)C(=O)OCC)NC(=O)CCC(O)=O)=CC=C1C1=CC=CC=C1 PYNXFZCZUAOOQC-UTKZUKDTSA-N 0.000 description 1
- 229960003953 sacubitril Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000002235 sarcomere Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013165 surgical myectomy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- VBHQKCBVWWUUKN-KZNAEPCWSA-N vernakalant Chemical compound C1=C(OC)C(OC)=CC=C1CCO[C@H]1[C@H](N2C[C@H](O)CC2)CCCC1 VBHQKCBVWWUUKN-KZNAEPCWSA-N 0.000 description 1
- 229960000527 vernakalant Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Definitions
- Atrial fibrillation is the most common type of cardiac arrhythmia, affecting more than 37 million people worldwide. As the global population ages, the prevalence of AF is expected to increase. Patients with AF are at increased risk for stroke, cognitive decline, and cardiovascular events and mortality. AF is associated with underlying disorders such as hypertension, coronary heart disease, rheumatic heart disease, heart failure, obesity, diabetes mellitus, and chronic kidney disease. Symptoms include, but are not limited to, heart palpitations, tachycardia, shortness of breath, weakness, dizziness, fatigue, chest pain, and confusion.
- AF is defined as a supraventricular tachyarrhythmia with uncoordinated atrial activation leading to ineffective atrial contraction, and can result from structural and/or electrical abnormalities of the atrium. Electrocardiographic characteristics include irregular R-R intervals (when AV conduction is present), no distinct repeating P waves, and irregular atrial activity. Episodes often increase in frequency and duration over time and become less responsive to medication. There are generally four types of AF (January et al., JACC (2014) 64(21):2246-80; Kirchhof et al., EurHeartJ (2016) 37:2893-2962). Paroxysmal AF, also known as intermittent or self-terminating AF, terminates within seven days of onset, either spontaneously or with intervention.
- Persistent AF is continuous AF that is sustained for more than seven days; pharmacologic or electrical cardioversion may be required to restore sinus rhythm.
- Longstanding persistent AF is continuous AF that is sustained for more than 12 months, and may not respond to medication or cardioversion.
- Permanent (chronic) AF is persistent AF where the patient and the doctor jointly decide to stop further attempts to restore and/or maintain sinus rhythm.
- AF impacts left atrial function and geometry, and vice-versa.
- AF is accompanied by a conversion from the fast a-myosin heavy chain (MHC) isoform to the slow P-MHC isoform (Narolska et al., Journal of Muscle Research and Cell Motility (2005) 26:39-48; Belus et al., Circulation Research (2010): 107(1): 144-52; Barth et al., Circulation Research (2005)
- LA left atrial
- LAEF LA emptying fraction
- LAEF impaired LA function
- LAEF new-onset atrial fibrillation
- LAFI Impaired LA functional index
- HCM hypertrophic cardiomyopathy
- AF is the most common arrhythmia in hypertrophic cardiomyopathy (HCM), and can cause significant impairment in the hearts of HCM patients. In some cases, AF can rapidly exacerbate HCM symptoms such as exertional dyspnea.
- Genetic (heritable) HCM comprises a group of highly penetrant, monogenic, autosomal dominant myocardial diseases. HCM can be caused by one or more of over 1,000 known point mutations in any one of the proteins contributing to the functional unit of myocardium, the sarcomere.
- HCM left ventricular hypertrophy unexplained by other known causes (e.g., hypertension or valvular disease), and many of these can be shown to have HCM, once other heritable (e.g., lysosomal storage diseases), metabolic, or infiltrative causes have been excluded. While many patients with HCM report minimal or no symptoms for extended periods of time, HCM is a progressive disease with a significant cumulative burden of morbidity, and has been associated with stroke, heart failure, and sudden cardiac death.
- LVOT left ventricular outflow tract
- obstructive HCM or oHCM obstructive HCM
- nHCM non-obstructive HCM
- the present disclosure provides a method of treating atrial dysfunction in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula I below (I) (Compound I), or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
- fluorine (F) optionally wherein the patient exhibits atrial fibrillation.
- the present disclosure further provides a method of treating atrial cardiomyopathy in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
- the present disclosure further provides a method of treating atrial tachyarrhythmia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
- the present disclosure further provides a method of treating atrial fibrillation in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e-g., F).
- a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e-g., F).
- the present disclosure further provides a method of reducing atrial fibrillation recurrence in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein atrial fibrillation recurrence is reduced by 10% or greater.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein atrial fibrillation recurrence is reduced by 10% or greater.
- the present disclosure further provides a method of reducing atrial fibrillation burden in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
- Atrial fibrillation burden is reduced by 10% or greater.
- the present disclosure further provides a method of reducing the duration of an atrial fibrillation episode in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the duration of the episode is reduced by 10% or greater.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the duration of the episode is reduced by 10% or greater.
- the present disclosure further provides a method of reducing the number of atrial fibrillation episodes during a monitoring period in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the number of atrial fibrillation episodes is reduced by 10% or greater.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the number of atrial fibrillation episodes is reduced by 10% or greater.
- the present disclosure further provides a method of maintaining sinus rhythm in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient has sustained atrial tachyarrhythmia for 12 months or less prior to the administering step, further optionally wherein the atrial tachyarrhythmia is atrial fibrillation.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F)
- the present disclosure further provides a method of restoring sinus rhythm in a patient exhibiting atrial tachyarrhythmia, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the cardioversion is electrical cardioversion and further optionally wherein the atrial tachyarrhythmia is atrial fibrillation.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F)
- the cardioversion is electrical cardioversion and further optionally wherein the atrial tachyarrhythmia is atrial fibrillation.
- the present disclosure further provides a method of preventing or slowing the conversion of a-myosin heavy chain (MHC) to P-MHC in the left atrium of a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
- MHC myosin heavy chain
- the present disclosure further provides a method of reversing the conversion of a-myosin heavy chain (MHC) to P-MHC in the left atrium of a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
- n is 0. In other embodiments, n is 1. In some embodiments of formula I, R is fluorine. In some embodiments, R is a fluorine at position 3 (meta position).
- the patient exhibits diastolic dysfunction, e.g., hypertrophic cardiomyopathy (HCM).
- HCM hypertrophic cardiomyopathy
- the HCM can be obstructive hypertrophic cardiomyopathy (oHCM), and in certain embodiments the patient has at least a 30 mm Hg pressure gradient across the left ventricular outflow tract (LVOT) at rest, during or immediately after a Valsalva maneuver, or post-exercise.
- LVOT left ventricular outflow tract
- nHCM nonobstructive hypertrophic cardiomyopathy
- the patient has heart failure and a diagnosis of any one of NYHA Class II-IV.
- the patient exhibits atrial fibrillation, and the therapeutically effective amount of Compound I alleviates one or more symptoms of HCM, maintains sinus rhythm, reduces atrial fibrillation recurrence, and/or prevents incident atrial fibrillation in the patient.
- the present disclosure also provides a method of preventing tachycardia-induced cardiomyopathy in a patient exhibiting atrial fibrillation, comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
- the patient has sustained tachyarrhythmia or atrial fibrillation for a duration of 12 months or less prior to the step of administering Compound I.
- the patient has an atrial fibrillation burden of 2-70%.
- the Compound I is administered to the patient orally.
- the patient has undergone an electrical cardioversion before or after the step of administering Compound I, optionally where the electrical cardioversion is performed no more than 24 hours before or after the administering step.
- an additional medication is administered for improving cardiovascular conditions in the patient.
- the method results in any one or combination of the following: a) reduced risk of urgent outpatient intervention for atrial dysfunction, diastolic dysfunction, or both; b) improved quality of life as measured through 6-MWT or KCCQ; c) improved exercise capacity; d) improvement in a patient’ s NYHA classification; e) delay in clinical worsening; f) reduction in severity of cardiovascular-related symptoms; g) increased left atrial ejection fraction (LAEF); h) decreased left atrial volume (LAminVI); i) improved left atrial function index (LAFI); j) reduced cTnT leakage; k) decreased BNP; and l) decreased expression of pro-fibrotic genes.
- the method results in reduced cardiovascular death, hospitalization, stroke, embolism, heart failure, or any combination thereof.
- the present disclosure also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), or a pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient, for use in a method described herein and/or for use in treating a disease as described herein.
- the present disclosure also provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), in the manufacture of a medicament for treating a patient in a method described herein and/or for treating a disease as described herein.
- a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F)
- compositions comprising Compound I and a pharmaceutically acceptable excipient (e.g., for use in any of the treatment methods described herein); Compound I and the pharmaceutical compositions for use in any of the treatment methods described herein; and the use of Compound I for the manufacture of a medicament for use in any of the treatment methods described herein.
- FIG. l is a schematic diagram showing the design for an experiment on the chronic effects of Compound A on HCM and on left atrial and left ventricular geometry and function in a mini-pig model of inherited HCM (“HCM pigs”)- Compound A dose is increased over the first 12 weeks of the study to account for weight gain.
- CMPD A Compound A.
- CTRL control.
- cMR cardiac MRI.
- PV LV pressure and volume studies (invasive hemodynamics).
- RNA LV gene expression studies.
- HIST histology. BIO: LV/LA fiber biomechanical studies.
- FIG. 2 depicts RNA expression levels in LV gene expression studies in HCM pigs.
- CMPD A Compound A.
- CTRL control.
- FIG. 3 is a set of graphs showing the effects of Compound A on left atrial (LA) geometry and function in HCM pigs.
- Compound A CMPD A
- LA volumes left panel
- Ktr preserved isometric tension redevelopment dynamics
- CTRL untreated HCM pig controls
- FIG. 4 is a graph showing the myosin ATPase inhibitory effect of Compound A and mavacamten in bovine cardiac myofibrils at pCa 6.0. The compounds demonstrate similar inhibition of myosin over the range of tested concentrations.
- CMPD compound.
- FIG. 5 is a graph showing the effects of Compound A and mavacamten in bovine cardiac myofibrils on disordered relaxed state (DRX) and super-relaxed state (SRX) ATPase rates.
- the present disclosure provides methods, uses, and compositions relating to treating patients with atrial dysfunction (e.g., AF), including patients with comorbid atrial dysfunction and diastolic dysfunction (impairment of the diastolic function of the heart; e.g., due to hypertrophic cardiomyopathy (HCM) , including both obstructive and non-obstructive HCM.
- atrial dysfunction e.g., AF
- diastolic dysfunction impairment of the diastolic function of the heart; e.g., due to hypertrophic cardiomyopathy (HCM) , including both obstructive and non-obstructive HCM.
- HCM hypertrophic cardiomyopathy
- compositions used in the present therapies contain Compound I as an active pharmaceutical ingredient (API).
- Compound I has the following chemical structural formula (I): or a pharmaceutically acceptable salt thereof, wherein R is a halogen (i.e., fluorine, chlorine, bromine, or iodine) and n is 0, 1, 2, 3, 4, or 5.
- R is a halogen (i.e., fluorine, chlorine, bromine, or iodine)
- n is 0, 1, 2, 3, 4, or 5.
- n is 0, and the compound is mavacamten with the following formula:
- R is fluorine and n is 1 or 2.
- n is i and R is a fluorine at position 3 (i.e., meta position), and the compound is termed Compound A, with the following formula: [0042]
- Compounds of formula (I) are selective allosteric inhibitors of cardiac myosin ATPase that can normalize the function of myosin in hypercontractile hearts. Because Compound I restores the contractile properties and energy demands of the heart, it may offer benefits such as prevention of left atrial remodeling.
- Compounds of Formula (I), (II) or (III) may be in the form of a pharmaceutically acceptable salt. In other embodiments, Compounds of Formula (I), (II) or (III) may be in the form of a free base.
- compositions used herein may be provided in an oral dosage form (e.g., a liquid, a suspension, an emulsion, a capsule, or a tablet).
- an oral dosage form e.g., a liquid, a suspension, an emulsion, a capsule, or a tablet.
- Compound I particles are compressed into tablets or capsules each containing 1, 2, 2.5, 5, 7.5, 10, 15, 20, or 25 mg of Compound I.
- Compound I particles may be suspended in a suitable liquid such as water, a suspending vehicle, and/or flavored syrup for oral administration.
- the pharmaceutical compositions of the present disclosure may also contain pharmaceutically acceptable excipients.
- the tablets used herein may contain bulking agents, diluents, binders, glidants, lubricants, and disintegrants.
- Compound I tablets contain one or more of microcrystalline cellulose, lactose monohydrate, hypromellose, croscarmellose sodium, and magnesium stearate. The tablets may be coated to make them easier to ingest.
- the therapies of the present disclosure may be used to treat a patient exhibiting atrial dysfunction.
- the patient may exhibit atrial fibrillation.
- Abnormal atrial contractility, volume, function, and/or atrial cardiomyopathy may contribute to the atrial dysfunction.
- the atrial dysfunction being treated includes, without limitation, atrial cardiomyopathy and atrial arrhythmia (e.g., atrial tachyarrhythmia) such as AF or atrial flutter.
- the atrial dysfunction e.g., atrial tachyarrhythmia
- the atrial dysfunction may be acute or chronic.
- the patient may have sustained the atrial dysfunction (e.g., atrial tachyarrhythmia such as AF) continuously for a duration of, e.g., no more than 10 years, 9 years, 8 years, 7 years, 6 years, 5 years, 4 years, 3 years, 2 years, 12 months, 9 months, 6 months, 3 months, 1 month, 2 weeks, or 1 week prior to a therapy of the present disclosure.
- the patient has AF, which may be clinically manifested or may be subclinical (asymptomatic).
- AF cases are caused by a heart valve disorder, they are termed valvular AF.
- AF without a diagnosed heart valve disorder is called non-valvular AF.
- non-valvular AF is AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair.
- the AF being treated may be, e.g., paroxysmal, persistent, or long-standing persistent.
- the AF is persistent but not long-standing persistent AF; that is, it has been sustained for 12 months or less.
- the patient has an AF burden of 1-70%, 2-70%, 3-70%, 1-99%, 2-99%, etc.
- AF burden refers to the amount of AF that an individual has.
- AF burden may be defined as the percentage of time in which a patient is in AF during a monitoring period.
- AF burden may be defined as the duration of a patient’s longest AF episode, or the number of AF episodes during a monitoring period.
- the patient has a genetic predisposition to AF, such as an inherited cardiomyopathy or channelopathy.
- the patient has an implanted device with an atrial lead (e.g., pacemaker, ICD, CRT), or an implantable loop recorder (ILR).
- an atrial lead e.g., pacemaker, ICD, CRT
- an implantable loop recorder ILR
- the patient has a Modified European Heart Rhythm Association (EHRA) symptom score of 1, 2a, 2b, 3, or 4, as defined in Table 1 below.
- EHRA Modified European Heart Rhythm Association
- the patient has been or is being treated with an anticoagulant, a rate control agent, a rhythm control agent, or any combination thereof, but continues to exhibit AF symptoms.
- AF symptoms may include, e.g., heart palpitations, tachycardia, fatigue, dizziness, weakness, chest discomfort, reduced exercise capacity, increased urination, shortness of breath, angina, presyncope, syncope, sleeping difficulties, confusion, and psychosocial distress, or any AF symptom described herein.
- the patient also exhibits diastolic dysfunction.
- Diastolic dysfunction may include, e.g., impaired left ventricle relaxation, filling, or diastolic distensibility, or left ventricle stiffness. In some embodiments, these traits may be measured using echocardiography.
- the diastolic dysfunction may be symptomatic or asymptomatic.
- Diastolic dysfunction is present or an important feature of a series of diseases including, but not limited to, hypertrophic cardiomyopathy (HCM), left ventricular hypetrophy (LVH) - including malignant LVH, heart failure with preserved ejection fraction (HFpEF) - including both disorders of active relaxation and disorders of chamber stiffness (diabetic HFpEF), dilated cardiomyopathy (DCM), ischemic cardiomyopathy, cardiac transplant allograft vasculopathy, restrictive cardiomyopathy - including inflammatory subgroups (e.g., Loefflers and EMF), infiltrative subgroups (e.g., amyloid, sarcoid and XRT), storage subgroups (e g., hemochromatosis, Fabry and glycogen storage disease), idiopathic/inherited subgroups such as Trop I (P-myosin HC), Trop T (a-cardiac actin) and desmin related (usually includes skeletal muscle), congenital heart disease
- the patient exhibiting atrial dysfunction also exhibits hypertrophic cardiomyopathy (HCM).
- HCM hypertrophic cardiomyopathy
- LV left ventricular
- HCM hypertrophic cardiomyopathy
- myocardial hypercontractility accompanied by reduced LV compliance, reflected clinically as reduced ventricular chamber size, often supranormal ejection fraction, increased wall thickness, and diastolic dysfunction.
- HCM patients Some of the symptoms that HCM patients have include, but are not limited to, shortness of breath (especially during exercise), chest pain (especially during exercise), fainting (especially during or just after exercise), sensation of rapid, fluttering or pounding heartbeats, and heart murmur.
- HCM is obstructive HCM. It is generally understood that obstructive HCM (oHCM) is defined as at least a 30 mm Hg (i.e., 30 mm Hg or higher) pressure gradient across the LVOT in an individual at rest, during or immediately after Valsalva maneuver, or post-exercise. In some embodiments, an individual with oHCM has an LVOT pressure gradient of at least 35, 40 mm Hg, 45 mm Hg or 50 mm Hg. In some embodiments, the pressure gradient across the LVOT in the individual is measured at rest. In some embodiments, the pressure gradient across the LVOT in the individual is measured during or immediately after a Valsalva maneuver is performed. In some embodiments, the pressure gradient across the LVOT in the individual is measured post-exercise. oHCM may lead to severe symptoms of heart failure, arrhythmias, and/or death.
- oHCM may lead to severe symptoms of heart failure, arrhythmias, and/or death.
- HCM is non-obstructive HCM.
- the patient additionally has one or more conditions selected from sleep apnea, hypertension, hyperlipidemia, hyperthyroidism, obesity, diabetes mellitus, glucose intolerance, alcohol use, tobacco use, prior myocardial infarction, chronic obstructive pulmonary disease, heart failure, coronary heart disease, rheumatic heart disease, valvular heart disease, nonvalvular heart disease, left ventricular hypertrophy, left ventricular diastolic dysfunction, and renal disease.
- sleep apnea hypertension
- hyperlipidemia hyperthyroidism
- obesity diabetes mellitus
- glucose intolerance glucose intolerance
- alcohol use tobacco use
- prior myocardial infarction chronic obstructive pulmonary disease
- heart failure coronary heart disease
- rheumatic heart disease valvular heart disease
- nonvalvular heart disease nonvalvular heart disease
- left ventricular hypertrophy left ventricular diastolic dysfunction
- renal disease selected from sleep apnea, hypertension
- the therapies of the present disclosure may be used to treat a patient with AF with or without diastolic dysfunction (e.g., HCM).
- the therapies may be used to maintain sinus rhythm (e.g., normal sinus rhythm) in a patient with AF, and/or may be used to reduce atrial fibrillation recurrence in a patient with AF.
- a therapy described herein may include the step of selecting a patient with a type of atrial dysfunction as described herein (e.g., AF).
- the patient is further selected as having a type of diastolic dysfunction as described herein (e.g., HCM).
- a patient treated by a therapy described herein has previously been or is being treated for the atrial dysfunction and/or diastolic dysfunction, with, for example, the standard of care for said condition(s), and has not shown adequate improvement with said treatment.
- the Compound I therapies described herein may treat atrial dysfunction (e.g., AF) in a patient.
- the patient may also have diastolic dysfunction such as HCM.
- the patient may receive a therapy of the present disclosure for at least one month, at least six months, at least twelve months, at least one year, or longer, or until such time the patient no longer needs the treatment.
- Compound I (e.g., mavacamten or Compound A) is administered in a total oral daily dosage of about 1 mg to 50 mg. In some embodiments, the total daily dosage is about 1 mg to 50 mg. In some embodiments, the total daily dosage of Compound I is about 2 mg to 30 mg, 10 mg to 20 mg, 2 mg to 10 mg, or 2 mg to 5 mg. In some embodiments, the total daily dosage of Compound I is 2.5 mg to 15 mg. In some embodiments, the total daily dosage of Compound I is 5 mg to 15 mg. In some embodiments, the total daily dosage of Compound I is 2 mg to 15 mg. In some embodiments, the total daily dosage of Compound I is 1 mg to 15 mg. In some embodiments, the effective amount to achieve and maintain the desired blood plasma concentration of Compound I is from 2.5 to 20 mg.
- the total daily dosage of Compound I is about 2 mg to 30 mg, 10 mg to 20 mg, 2 mg to 10 mg, or 2 mg to 5 mg. In some embodiments, the total daily dosage of Compound I is 2.5 mg to
- Compound I e.g., mavacamten or Compound A
- a total oral daily dosage e.g., once daily
- the dosage used for a particular patient may be adjusted based on the patient’s condition and/or the patient’s unique PK profile.
- Compound I e.g., mavacamten or Compound A
- is dosed such that its plasma concentration in the subject is between 225-600 ng/mL, 350-700 ng/mL, or 150-600 ng/mL.
- Compound I is dosed such that its plasma concentration in the subject is between 200-400 ng/mL.
- the Compound I plasma concentration may be determined by any method known in the art, such as, for example, high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LC-MS such as high performance LC-MS), gas chromatography (GC), or any combination thereof.
- HPLC high performance liquid chromatography
- LC-MS liquid chromatography-mass spectroscopy
- GC gas chromatography
- Compound I is administered to the patient at a dose whereby the LVOT within the subject decreases without a significant change in LVEF.
- administration of Compound I or a pharmaceutical composition containing Compound I (“Compound I medication”) includes self-administration by the patient himself or herself (e.g., oral intake by the patient).
- Compound I is mavacamten.
- the present disclosure provides both Compound I monotherapy and combination therapy.
- a Compound I regimen of the present disclosure is used in combination with an additional therapy regimen, e.g., a guideline-directed medical therapy (GDMT), also referred to as a standard of care (SOC) therapy, for one or more cardiac conditions exhibited by the patient, or other therapy useful for treating the relevant disease or disorder.
- GDMT guideline-directed medical therapy
- SOC standard of care
- the additional therapeutic agent may be administered by a route and in an amount commonly used for said agent or at a reduced amount, and may be administered simultaneously, sequentially, or concurrently with Compound I.
- Compound I is administered on top of the SOC for a condition of atrial dysfunction, such as atrial fibrillation; a condition of diastolic dysfunction, such as HCM; or both.
- the patient exhibiting atrial dysfunction is given, in addition to the Compound I medication, another therapeutic agent for treating the atrial dysfunction.
- the therapeutic agent is an antithrombotic agent (e.g., an anticoagulant such as a novel oral anticoagulant (NOAC)), a rate control agent, an anti arrhythmic agent (e.g., a Class la, Ic, or III anti arrhythmic agent), a pharmacological cardioversion agent, a RAAS inhibitor, etc.
- an antithrombotic agent e.g., an anticoagulant such as a novel oral anticoagulant (NOAC)
- NOAC novel oral anticoagulant
- an anti arrhythmic agent e.g., a Class la, Ic, or III anti arrhythmic agent
- a pharmacological cardioversion agent e.g., a RAAS inhibitor, etc.
- the Compound I medication is administered to a patient who has had or plans to have a non-pharmacological intervention such as electrical cardioversion, left atrial appendage occlusion/excision, atrioventricular nodal ablation (e.g., with permanent ventricular pacing), AF catheter ablation, AF surgical ablation (e.g., Maze procedure), pulmonary vein ablation, or a permanent pacemaker. Any combination of the above agents and interventions is also contemplated.
- a non-pharmacological intervention such as electrical cardioversion, left atrial appendage occlusion/excision, atrioventricular nodal ablation (e.g., with permanent ventricular pacing), AF catheter ablation, AF surgical ablation (e.g., Maze procedure), pulmonary vein ablation, or a permanent pacemaker. Any combination of the above agents and interventions is also contemplated.
- the Compound I medication is administered to the patient in place of an anti arrhythmic agent.
- the patient may have had prior treatment with an anti arrhythmic agent that is then replaced by the Compound I medication, or the patient may be treated with the Compound I medication without prior treatment with an anti arrhythmic agent.
- a patient with atrial dysfunction e.g., AF
- a beta blocker in addition to the Compound I medication.
- a patient with atrial dysfunction e.g., AF
- an anticoagulant e.g., a NOAC
- a rate control agent e.g., a beta blocker, digoxin, and/or amiodarone
- a patient with atrial dysfunction e.g., AF
- an anticoagulant e.g., a NOAC
- a rate control agent e.g., a beta blocker, digoxin, and/or amiodarone
- a patient with atrial dysfunction e.g., AF
- cardioversion e.g., electrical cardioversion
- a patient with atrial dysfunction e.g., AF
- cardioversion e.g., electrical cardioversion
- an anti arrhythmic drug e.g., amiodarone, sotalol, or dofetilide
- the patient exhibiting diastolic dysfunction in addition to the atrial dysfunction (e.g., AF) is given, in addition to the Compound I medication and optionally a therapeutic agent for treating the atrial dysfunction as described herein, another therapeutic agent for treating the diastolic dysfunction.
- the therapeutic agent is a beta blocker, a calcium channel blocker (e.g., a non-dihydropyridine calcium channel blocker), disopyramide, or any combination thereof.
- the beta blockers and/or calcium channel blockers are selected from those described herein, in any combination.
- a patient with atrial dysfunction e.g., AF
- diastolic dysfunction e.g., HCM
- surgical myectomy in addition to Compound I medication.
- a patient with atrial dysfunction e.g., AF
- diastolic dysfunction e.g., HCM
- alcohol septal ablation in addition to Compound I medication.
- a patient with atrial dysfunction e.g., AF
- diastolic dysfunction e.g., HCM
- an anticoagulant e.g., an oral anticoagulant (OAC)
- OAC oral anticoagulant
- a patient with atrial dysfunction e.g., AF
- diastolic dysfunction e.g., HCM
- amiodarone and/or disopyramide combined with a beta blocker and/or a nondihydropyridine calcium channel antagonist in addition to the Compound I medication.
- a patient with atrial dysfunction e.g., AF
- diastolic dysfunction e.g., HCM
- sotalol, dofetilide, and/or dronedarone is treated with sotalol, dofetilide, and/or dronedarone in addition to the Compound I medication.
- a patient with atrial dysfunction e.g., AF
- diastolic dysfunction e.g., HCM
- ARNI angiotensin receptor neprilysin inhibitor
- the patient is treated with sacubitril, valsartan, or Entresto® in addition to the Compound I medication.
- Compound I is administered to a patient with atrial dysfunction (e.g., AF) on top of the SOC for obstructive or non-obstructive HCM in combination with AF.
- atrial dysfunction e.g., AF
- Suitable anti arrhythmic medications may include, e.g., amiodarone, dronedarone, propafenone, flecainide, dofetilide, ibutilide, quinidine, procainamide, disopyramide, and sotalol.
- the anti arrhythmic medications are of Class la, Ic, or III.
- Suitable anticoagulants may include, e.g., warfarin, apixaban, rivaroxaban, edoxaban, and dabigatran.
- the anticoagulants are oral anticoagulants (OACs); in certain embodiments, OACs may be administered with vitamin K antagonists.
- the anticoagulants are non-vitamin K oral anticoagulants (NOACs).
- Suitable pharmacological cardioversion agents include, e.g., flecainide, dofetilide, propafenone, ibutilide, vernakalant, etc.
- Suitable rate control agents include, e.g., beta blockers, non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem), digitalis, and amiodarone.
- Suitable beta blockers include, e.g., bisoprolol, carvedilol, carvedilol CR, atenolol, esmolol, propranolol, nadolol, metaprolol tartrate, and metoprolol succinate extended release (metoprolol CR/XL)).
- Compound I is administered in combination with lifestyle changes such as reducing alcohol or caffeine intake, quitting smoking, limiting stimulants, achieving or maintaining a healthy weight, physical activity, treating sleep apnea, and/or controlling high blood pressure and/or blood sugar levels, or any combination thereof.
- lifestyle changes such as reducing alcohol or caffeine intake, quitting smoking, limiting stimulants, achieving or maintaining a healthy weight, physical activity, treating sleep apnea, and/or controlling high blood pressure and/or blood sugar levels, or any combination thereof.
- the patient may be treated for the adverse effect.
- a patient experiencing headache due to the Compound I treatment may be treated with an analgesic such as ibuprofen and acetaminophen.
- the therapies of the present disclosure treat and/or ameliorate atrial dysfunction.
- the therapies also treat and/or ameliorate diastolic dysfunction.
- the terms “treat,” “treating” and “treatment” refer to any indicia of success in the treatment or amelioration of a pathology, injury, condition, or symptom related to the dysfunction, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms; making the pathology, injury, condition, or symptom more tolerable to the patient; decreasing the frequency or duration of the pathology, injury, condition, or symptom; or, in some situations, delaying or preventing the onset of the pathology, injury, condition, or symptom.
- Treatment or amelioration can be based on any objective or subjective parameter, including, e.g., the result of a physical examination.
- treatment of atrial dysfunction encompasses, but is not limited to, any one or combination of: improving atrial myocyte contractility, improving atrial contractility, improving atrial cardiomyopathy, improving atrial arrhythmia (e.g., tachyarrhythmia), reducing AF recurrence, reducing AF burden, preventing incident AF, maintaining sinus rhythm (e.g., after cardioversion), restoring sinus rhythm (e.g., in combination with cardioversion), decreasing left atrial volume, increasing left atrial emptying fraction, increasing left atrial function index, preventing conversion of a-MHC to 0-MHC in the LA, and alleviating or preventing the symptoms of atrial dysfunction.
- atrial dysfunction e.g., AF
- atrial dysfunction encompasses, but is not limited to, any one or combination of: improving atrial myocyte contractility, improving atrial contractility, improving atrial cardiomyopathy, improving atrial arrhythmia (e.g., tachyarrhythmia), reducing AF recurrence,
- Symptoms of atrial dysfunction may include, e.g., heart palpitations, tachycardia, fatigue, dizziness, weakness, chest discomfort, reduced exercise capacity, increased urination, shortness of breath, angina, presyncope, syncope, sleeping difficulties, confusion, and psychosocial distress.
- Treatment of diastolic dysfunction encompasses, but is not limited to, any one or combination of improving the cardiac functions of the patient and alleviating or preventing the symptoms of diastolic dysfunction (especially during exercise, including walking or stair climbing).
- Symptoms of diastolic dysfunction such as HCM may include, e.g., shortness of breath (especially during exercise), chest pain (especially during exercise), fainting (especially during or just after exercise), sensation of rapid, fluttering or pounding heartbeats, atrial and ventricular arrhythmias, heart murmur, hypertrophied and non-dilated left ventricle, thickened heart muscle, thickened left ventricular wall, elevated pressure gradient across left ventricular outflow tract (LVOT), elevated post-exercise LVOT gradient, and high left ventricular ejection fraction (LVEF).
- LVOT left ventricular outflow tract
- LVEF high left ventricular ejection fraction
- the therapies of the present disclosure reduce AF burden and/or AF recurrence in a patient (e.g., a patient from a population described herein).
- AF burden and/or AF recurrence may be reduced by 10% or greater.
- AF burden and/or AF recurrence are reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or greater, or 100%.
- the percentage of time the patient spends in AF during a monitoring period is reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or greater, or 100%.
- the therapies reduce the duration of a patient’s longest AF episode, or the number of AF episodes during a monitoring period, e.g., by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or greater, or 100%.
- the monitoring period may be 24 hours, 1 week, 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or more.
- the therapies of the present disclosure maintain sinus rhythm (e.g., normal sinus rhythm) in a patient (e.g., a patient from a population described herein).
- the patient has been treated with or will be treated with cardioversion (e.g., electrical cardioversion).
- cardioversion e.g., electrical cardioversion
- the therapies of the present disclosure, in combination with cardioversion (e.g., electrical cardioversion) restore sinus rhythm (e.g., normal sinus rhythm) in a patient.
- sinus rhythm is maintained for at least one, two, three, four, five, six, or seven days; at least one, two, three, or four weeks; at least one, two, three, four, five, six, nine, or twelve months; at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 years; or longer; or until such time that the patient no longer needs the treatment.
- the therapies of the present disclosure reduce the risk of, or delay the incidence of, myocardial infarction, ventricular arrhythmia, heart failure, chronic kidney disease, end-stage renal disease, sudden cardiac death, or all-cause death in a patient.
- the therapies of the present disclosure improve the patient’s quality of life, as measured by the 6-Month Walk Test (6-MWT), Kansas City Cardiomyopathy Questionnaire (KCCQ), Atrial Fibrillation Effect on Quality-of-Life (AFEQT) measure, and/or Mayo AF-Specific Symptom Inventory (MAFSI).
- the therapies of the present disclosure prevent or delay tachycardia-induced cardiomyopathy in patients exhibiting atrial fibrillation.
- the therapies of the present disclosure prevent or delay incident AF (initial occurrence of AF) in patients. Additionally or alternatively, the therapies may prevent or delay AF recurrence in patients.
- PD Pharmacodynamic
- the therapies of the present disclosure :
- LAminVi in the patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more;
- LA ma xVi in the patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more; and/or - increase LAFI in the patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more.
- the therapies of the present disclosure reduce biomechanical remodeling of the left atrium, such as increased maximal force and slowed cross-bridge formation rates (e.g., in a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM).
- the therapies of the present disclosure prevent, slow, and/or reverse the conversion of a-myosin heavy chain (MHC) to p-MHC in the left atrium of a patient by 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more (e.g., in a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM).
- MHC a-myosin heavy chain
- the therapies of the present disclosure are identical to [0106] in some embodiments.
- cTnT leakage by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more;
- cTNT a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM.
- the cTnT is high sensitivity cTnT.
- the therapies of the present disclosure downregulate BNP and/or pro-fibrotic genes (e.g., SPP1, NPPB, TGF-01, TGF-P2, FN1, CCN2, or any combination thereof) by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more.
- BNP and/or pro-fibrotic genes e.g., SPP1, NPPB, TGF-01, TGF-P2, FN1, CCN2, or any combination thereof
- the therapies of the present disclosure reduce mortality in a patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more (e.g., in a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM).
- the patient treated with a therapy described herein may exhibit New York Heart Association (NYHA) Class I, II, III, or IV heart failure, as defined in Table 2 below.
- NYHA New York Heart Association
- the patient has NYHA Class II- IV heart failure.
- the therapies of the present disclosure improve, stabilize, or delay worsening of the NYHA functional classification of the patient. Table 2.
- NYHA New York Heart Association
- the present therapies may reduce the risk of cardiovascular death, and/or the risk, frequency, or duration of hospitalization/urgent care visits, for a patient population described herein.
- the hospitalization and urgent care visits may be for atrial dysfunction as described herein, diastolic dysfunction as described herein, or both.
- “reducing the risk” of an event means increasing the time to the event by at least 10% (e.g., at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more).
- the risk can be relative risk or absolute risk.
- the present therapies reduce the frequency of hospitalization and urgent care visits by at least 10% (e.g., at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). In some embodiments, the present therapies reduce the duration of hospitalization by at least 10% (e.g., at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
- the present invention also provides articles of manufacture, e.g., kits, comprising one or more dosages of the Compound I medication, and instructions for patients (e.g., for treatment in accordance with a method described herein).
- the articles of manufacture may also contain an additional therapeutic agent in the case of combination therapy.
- Compound I tablets or capsules may be blistered and then carded, produced with, for example, 5-20 tablets per blister card; each tablet or capsule may contain 1, 2, 2.5, 5, 7.5, 10, 15, 20, or 25 mg of Compound I, and such blister card may or may not additionally include a loading dose tablet or capsule.
- the present disclosure also includes methods for manufacturing said articles.
- Example 1 Chronic Treatment with Compound A in a Mini-Pig Model of Inherited
- This Example describes an in vivo study that evaluates the chronic effects of Compound A, in a genetic large-animal model of HCM.
- HCM pigs Young ( ⁇ 1 month) cloned Yucatan mini-pigs with a heterozygous MYH7 R403Q mutation (“HCM pigs”) were treated and evaluated as shown in FIG. 1.
- the pigs treated with Compound A were divided into two cohorts: A and B. Treated animals received progressively increasing Compound A doses (5, 7.5, 10, and 15 mg/day PO) to account for weight gain.
- pigs After 14 weeks of treatment, pigs underwent in vivo cardiac MRI (cMR) imaging, including T1 mapping and extracellular volume (ECV) assessments.
- cMR cardiac MRI
- ECV extracellular volume
- biomechanical studies were performed in skinned left-ventricular (LV) and left-atrial (LV) fibers.
- LA fibers from untreated HCM pigs showed biomechanical remodeling characteristic of chronic overload: increased maximal force (21.8 ⁇ 1.5# vs. 14.7 ⁇ 1.4 mN/mm2 in WT) and slowed cross-bridge formation rates (Kt r : 4.9 ⁇ 0.4 # vs. 6.6 ⁇ 0.6 s-1 in WT) consistent with a switch towards slow-myosin isoforms.
- Compound A prevented this remodeling (e.g., Ktr: 8.1 ⁇ 1.3 s-1*), preserving normal LA (fast) myosin content and isometric tension redevelopment dynamics (FIG. 3). *, #: P ⁇ 0.05 vs. CTRL or WT.
- Mavacamten is a cardiac-specific, small-molecule allosteric modulator of B-cardiac myosin that reversibly inhibits its binding to actin.
- Compound A is a mavacamten surrogate in which a hydrogen has been substituted with fluorine.
- both compounds were tested in bovine cardiac myofibrils for inhibition of myosin ATPase.
- pCa 6.0 Compound A and mavacamten exhibited similar inhibition of myosin ATPase activity over the tested concentration range (FIG. 4).
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein are methods, uses, and compositions for treating atrial fibrillation in a patient, such as a patient exhibiting hypertrophic cardiomyopathy.
Description
MAVACAMTEN AND DERIVATIVES THEREOF FOR USE IN TREATING ATRIAL DYSFUNCTION
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. provisional application no. 63/381,966, filed November 2, 2022, the entire contents of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] Atrial fibrillation (AF) is the most common type of cardiac arrhythmia, affecting more than 37 million people worldwide. As the global population ages, the prevalence of AF is expected to increase. Patients with AF are at increased risk for stroke, cognitive decline, and cardiovascular events and mortality. AF is associated with underlying disorders such as hypertension, coronary heart disease, rheumatic heart disease, heart failure, obesity, diabetes mellitus, and chronic kidney disease. Symptoms include, but are not limited to, heart palpitations, tachycardia, shortness of breath, weakness, dizziness, fatigue, chest pain, and confusion.
[0003] AF is defined as a supraventricular tachyarrhythmia with uncoordinated atrial activation leading to ineffective atrial contraction, and can result from structural and/or electrical abnormalities of the atrium. Electrocardiographic characteristics include irregular R-R intervals (when AV conduction is present), no distinct repeating P waves, and irregular atrial activity. Episodes often increase in frequency and duration over time and become less responsive to medication. There are generally four types of AF (January et al., JACC (2014) 64(21):2246-80; Kirchhof et al., EurHeartJ (2016) 37:2893-2962). Paroxysmal AF, also known as intermittent or self-terminating AF, terminates within seven days of onset, either spontaneously or with intervention. Persistent AF is continuous AF that is sustained for more than seven days; pharmacologic or electrical cardioversion may be required to restore sinus rhythm. Longstanding persistent AF is continuous AF that is sustained for more than 12 months, and may not respond to medication or cardioversion. Permanent (chronic) AF is persistent AF where the patient and the doctor jointly decide to stop further attempts to restore and/or maintain sinus rhythm.
[0004] AF impacts left atrial function and geometry, and vice-versa. AF is accompanied by a conversion from the fast a-myosin heavy chain (MHC) isoform to the slow P-MHC isoform
(Narolska et al., Journal of Muscle Research and Cell Motility (2005) 26:39-48; Belus et al., Circulation Research (2010): 107(1): 144-52; Barth et al., Circulation Research (2005)
96(9): 1022-9); Eiras et al., Journal of Molecular and Cellular Cardiology (2006) 41 :467-77), reducing the speed of atrial contraction and relaxation. Over time, AF can result in decreased left atrial (LA) function (e.g., LA emptying fraction (LAEF)), as well as atrial remodeling (e.g., fibrosis and/or an increase in LA volumes that may become irreversible). Moreover, impaired LA function (e.g., LAEF) is associated with new-onset atrial fibrillation (Hirose et al., Eur Heart J. (2012) 13 (3) :243-50) as well as recurrence of AF after corrective procedures such as ablation. LA enlargement is strongly correlated with AF recurrence after electrical cardioversion.
Impaired LA functional index (LAFI), calculated from LAEF, indexed maximal LA volume, and left ventricular outflow tract velocity time integral, is associated with adverse atrial remodeling, and increases the risk of developing incident AF and/or cardiovascular disease even when left atrial size is normal (Sardana et al., J Am Soc Echocardiogr. (2017) 30(9):904- 12). LA parameters have been shown in observational studies to be powerful independent predictors of cardiovascular outcomes, including AF (Von Jeinsen et al., J Am Soc Echocardiograph. (2019) 33(l):72-81 ; Schaaf et al., Eur Heart J Cardiovasc Imaging (2017) 18:46-53).
[0005] AF is the most common arrhythmia in hypertrophic cardiomyopathy (HCM), and can cause significant impairment in the hearts of HCM patients. In some cases, AF can rapidly exacerbate HCM symptoms such as exertional dyspnea. Genetic (heritable) HCM comprises a group of highly penetrant, monogenic, autosomal dominant myocardial diseases. HCM can be caused by one or more of over 1,000 known point mutations in any one of the proteins contributing to the functional unit of myocardium, the sarcomere. About 1 in 500 individuals in the general population are found to have left ventricular hypertrophy unexplained by other known causes (e.g., hypertension or valvular disease), and many of these can be shown to have HCM, once other heritable (e.g., lysosomal storage diseases), metabolic, or infiltrative causes have been excluded. While many patients with HCM report minimal or no symptoms for extended periods of time, HCM is a progressive disease with a significant cumulative burden of morbidity, and has been associated with stroke, heart failure, and sudden cardiac death. In approximately 60% of patients with HCM, the left ventricular outflow tract (LVOT) becomes obstructed (obstructive HCM or oHCM), impeding the flow of blood and creating a pressure gradient between the LV cavity and the aorta. In other patients, the thickened heart muscle does
not block the LVOT, and disease is driven by diastolic impairment due to the enlarged and stiffened heart muscle (non-obstructive HCM or nHCM). Patients with combined AF and HCM are at increased risk of stroke, heart failure, and death.
[0006] Current therapies for AF include rate and rhythm control strategies and corrective procedures such as surgery (e.g., ablation) and sinus rhythm-restoring cardioversion. However, impaired LA function and geometry contribute to AF recurrence after corrective treatment; no current therapies directly address both depressed atrial function and atrial enlargement.
Accordingly, there remains a high medical need for new safe, well-tolerated, effective therapies for improving the atrial function of patients with AF, optionally when paired with other forms of cardiac dysfunction such as diastolic dysfunction (e.g., hypertrophic cardiomyopathy).
SUMMARY OF THE INVENTION
[0007] The present disclosure provides a method of treating atrial dysfunction in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula I below (I) (Compound I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
(e.g., fluorine (F)), optionally wherein the patient exhibits atrial fibrillation.
[0008] The present disclosure further provides a method of treating atrial cardiomyopathy in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
[0009] The present disclosure further provides a method of treating atrial tachyarrhythmia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
[0010] The present disclosure further provides a method of treating atrial fibrillation in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e-g., F).
[0011] The present disclosure further provides a method of reducing atrial fibrillation recurrence in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein atrial fibrillation recurrence is reduced by 10% or greater.
[0012] The present disclosure further provides a method of reducing atrial fibrillation burden in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
(e.g., F), optionally wherein atrial fibrillation burden is reduced by 10% or greater.
[0013] The present disclosure further provides a method of reducing the duration of an atrial fibrillation episode in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the duration of the episode is reduced by 10% or greater.
[0014] The present disclosure further provides a method of reducing the number of atrial fibrillation episodes during a monitoring period in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the number of atrial fibrillation episodes is reduced by 10% or greater.
[0015] The present disclosure further provides a method of maintaining sinus rhythm in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient has sustained atrial tachyarrhythmia for 12 months or less prior to the administering step, further optionally wherein the atrial tachyarrhythmia is atrial fibrillation.
[0016] The present disclosure further provides a method of restoring sinus rhythm in a patient exhibiting atrial tachyarrhythmia, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the cardioversion is electrical cardioversion and further optionally wherein the atrial tachyarrhythmia is atrial fibrillation.
[0017] The present disclosure further provides a method of preventing or slowing the conversion of a-myosin heavy chain (MHC) to P-MHC in the left atrium of a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), optionally wherein the patient exhibits atrial fibrillation.
[0018] The present disclosure further provides a method of reversing the conversion of a-myosin heavy chain (MHC) to P-MHC in the left atrium of a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
(e.g., F), optionally wherein the patient exhibits atrial fibrillation.
[0019] In the methods described herein, in some embodiments of formula I, n is 0. In other embodiments, n is 1. In some embodiments of formula I, R is fluorine. In some embodiments, R is a fluorine at position 3 (meta position).
[0020] In some embodiments of the methods described herein, the patient exhibits diastolic dysfunction, e.g., hypertrophic cardiomyopathy (HCM). The HCM can be obstructive hypertrophic cardiomyopathy (oHCM), and in certain embodiments the patient has at least a 30 mm Hg pressure gradient across the left ventricular outflow tract (LVOT) at rest, during or immediately after a Valsalva maneuver, or post-exercise. Alternatively, the HCM can be nonobstructive hypertrophic cardiomyopathy (nHCM).
[0021] In some embodiments of the methods described herein, the patient has heart failure and a diagnosis of any one of NYHA Class II-IV.
[0022] In some embodiments of the methods described herein, the patient exhibits atrial fibrillation, and the therapeutically effective amount of Compound I alleviates one or more symptoms of HCM, maintains sinus rhythm, reduces atrial fibrillation recurrence, and/or prevents incident atrial fibrillation in the patient.
[0023] The present disclosure also provides a method of preventing tachycardia-induced cardiomyopathy in a patient exhibiting atrial fibrillation, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen
(e.g., F).
[0024] In some embodiments of the methods described herein, the patient has sustained tachyarrhythmia or atrial fibrillation for a duration of 12 months or less prior to the step of administering Compound I.
[0025] In some embodiments of the methods described herein, the patient has an atrial fibrillation burden of 2-70%.
[0026] In some embodiments of the methods described herein, the Compound I is administered to the patient orally.
[0027] In some embodiments of the methods described herein, the patient has undergone an electrical cardioversion before or after the step of administering Compound I, optionally where the electrical cardioversion is performed no more than 24 hours before or after the administering step.
[0028] In some embodiments of the methods described herein, an additional medication is administered for improving cardiovascular conditions in the patient.
[0029] In some embodiments of the methods described herein, the method results in any one or combination of the following: a) reduced risk of urgent outpatient intervention for atrial dysfunction, diastolic dysfunction, or both; b) improved quality of life as measured through 6-MWT or KCCQ; c) improved exercise capacity; d) improvement in a patient’ s NYHA classification; e) delay in clinical worsening; f) reduction in severity of cardiovascular-related symptoms; g) increased left atrial ejection fraction (LAEF); h) decreased left atrial volume (LAminVI); i) improved left atrial function index (LAFI); j) reduced cTnT leakage; k) decreased BNP; and l) decreased expression of pro-fibrotic genes.
[0030] In some embodiments of the methods described herein, the method results in reduced cardiovascular death, hospitalization, stroke, embolism, heart failure, or any combination thereof. [0031] The present disclosure also provides a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), or a pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient, for use in a method described herein and/or for use in treating a disease as described herein.
[0032] The present disclosure also provides the use of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen (e.g., F), in the manufacture of a medicament for treating a patient in a method described herein and/or for treating a disease as described herein.
[0033] Also provided in the present disclosure are pharmaceutical compositions comprising Compound I and a pharmaceutically acceptable excipient (e.g., for use in any of the treatment methods described herein); Compound I and the pharmaceutical compositions for use in any of the treatment methods described herein; and the use of Compound I for the manufacture of a medicament for use in any of the treatment methods described herein.
[0034] Other features, objects, and advantages of the invention are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments and aspects of the invention, is given by way of illustration only, not limitation. Various changes and modification within the scope of the invention will become apparent to those skilled in the art from the detailed description.
BRIEF DESCRIPTION OF THE FIGURES
[0035] FIG. l is a schematic diagram showing the design for an experiment on the chronic effects of Compound A on HCM and on left atrial and left ventricular geometry and function in a mini-pig model of inherited HCM (“HCM pigs”)- Compound A dose is increased over the first 12 weeks of the study to account for weight gain. CMPD A: Compound A. CTRL: control. cMR: cardiac MRI. PV: LV pressure and volume studies (invasive hemodynamics). RNA: LV gene expression studies. HIST: histology. BIO: LV/LA fiber biomechanical studies.
[0036] FIG. 2 depicts RNA expression levels in LV gene expression studies in HCM pigs. CMPD A: Compound A. CTRL: control.
[0037] FIG. 3 is a set of graphs showing the effects of Compound A on left atrial (LA) geometry and function in HCM pigs. Compound A (CMPD A) decreased LA volumes (left panel), prevented the conversion of a-MHC to p-MHC in the LA (middle panel), and preserved isometric tension redevelopment dynamics (Ktr) (right panel), in comparison to untreated HCM pig controls (CTRL).
[0038] FIG. 4 is a graph showing the myosin ATPase inhibitory effect of Compound A and mavacamten in bovine cardiac myofibrils at pCa 6.0. The compounds demonstrate similar inhibition of myosin over the range of tested concentrations. CMPD: compound.
[0039] FIG. 5 is a graph showing the effects of Compound A and mavacamten in bovine cardiac myofibrils on disordered relaxed state (DRX) and super-relaxed state (SRX) ATPase rates.
DETAILED DESCRIPTION OF THE INVENTION
[0040] The present disclosure provides methods, uses, and compositions relating to treating patients with atrial dysfunction (e.g., AF), including patients with comorbid atrial dysfunction and diastolic dysfunction (impairment of the diastolic function of the heart; e.g., due to hypertrophic cardiomyopathy (HCM) , including both obstructive and non-obstructive HCM.
Pharmaceutical Compositions
[0041] The pharmaceutical compositions used in the present therapies contain Compound I as an active pharmaceutical ingredient (API). Compound I has the following chemical structural formula (I):
or a pharmaceutically acceptable salt thereof, wherein R is a halogen (i.e., fluorine, chlorine, bromine, or iodine) and n is 0, 1, 2, 3, 4, or 5. In some embodiments, n is 0, and the compound is mavacamten with the following formula:
(II).
In some embodiments, R is fluorine and n is 1 or 2. In some embodiments, n is i and R is a fluorine at position 3 (i.e., meta position), and the compound is termed Compound A, with the following formula:
[0042] Compounds of formula (I) (collectively “Compound f’ herein) are selective allosteric inhibitors of cardiac myosin ATPase that can normalize the function of myosin in hypercontractile hearts. Because Compound I restores the contractile properties and energy demands of the heart, it may offer benefits such as prevention of left atrial remodeling.
[0043] In some embodiments, Compounds of Formula (I), (II) or (III) may be in the form of a pharmaceutically acceptable salt. In other embodiments, Compounds of Formula (I), (II) or (III) may be in the form of a free base.
[0044] The pharmaceutical compositions used herein may be provided in an oral dosage form (e.g., a liquid, a suspension, an emulsion, a capsule, or a tablet). In some embodiments, Compound I particles are compressed into tablets or capsules each containing 1, 2, 2.5, 5, 7.5, 10, 15, 20, or 25 mg of Compound I. In some embodiments, Compound I particles may be suspended in a suitable liquid such as water, a suspending vehicle, and/or flavored syrup for oral administration.
[0045] Besides the Compound I API, the pharmaceutical compositions of the present disclosure may also contain pharmaceutically acceptable excipients. For example, the tablets used herein may contain bulking agents, diluents, binders, glidants, lubricants, and disintegrants. In some embodiments, Compound I tablets contain one or more of microcrystalline cellulose, lactose monohydrate, hypromellose, croscarmellose sodium, and magnesium stearate. The tablets may be coated to make them easier to ingest.
Patient Populations
[0046] The therapies of the present disclosure may be used to treat a patient exhibiting atrial dysfunction. For example, the patient may exhibit atrial fibrillation. Abnormal atrial contractility, volume, function, and/or atrial cardiomyopathy may contribute to the atrial dysfunction.
[0047] The atrial dysfunction being treated includes, without limitation, atrial cardiomyopathy and atrial arrhythmia (e.g., atrial tachyarrhythmia) such as AF or atrial flutter. The atrial dysfunction (e.g., atrial tachyarrhythmia) may be acute or chronic. In certain embodiments, the patient may have sustained the atrial dysfunction (e.g., atrial tachyarrhythmia such as AF) continuously for a duration of, e.g., no more than 10 years, 9 years, 8 years, 7 years, 6 years, 5
years, 4 years, 3 years, 2 years, 12 months, 9 months, 6 months, 3 months, 1 month, 2 weeks, or 1 week prior to a therapy of the present disclosure.
[0048] In some embodiments, the patient has AF, which may be clinically manifested or may be subclinical (asymptomatic). Where AF cases are caused by a heart valve disorder, they are termed valvular AF. AF without a diagnosed heart valve disorder is called non-valvular AF. For example, in some embodiments non-valvular AF is AF in the absence of rheumatic mitral stenosis, a mechanical or bioprosthetic heart valve, or mitral valve repair. In terms of timing and duration, the AF being treated may be, e.g., paroxysmal, persistent, or long-standing persistent. In some cases, the AF is persistent but not long-standing persistent AF; that is, it has been sustained for 12 months or less. In certain embodiments, the patient has an AF burden of 1-70%, 2-70%, 3-70%, 1-99%, 2-99%, etc. Unless otherwise indicated, AF burden refers to the amount of AF that an individual has. In some embodiments, AF burden may be defined as the percentage of time in which a patient is in AF during a monitoring period. In some embodiments, AF burden may be defined as the duration of a patient’s longest AF episode, or the number of AF episodes during a monitoring period.
[0049] In some embodiments, the patient has a genetic predisposition to AF, such as an inherited cardiomyopathy or channelopathy.
[0050] In some embodiments, the patient has an implanted device with an atrial lead (e.g., pacemaker, ICD, CRT), or an implantable loop recorder (ILR).
[0051] In some embodiments, the patient has a Modified European Heart Rhythm Association (EHRA) symptom score of 1, 2a, 2b, 3, or 4, as defined in Table 1 below.
Table 1. Modified EHRA Symptom Scale
[0052] In some embodiments, the patient has been or is being treated with an anticoagulant, a rate control agent, a rhythm control agent, or any combination thereof, but continues to exhibit AF symptoms. Such symptoms may include, e.g., heart palpitations, tachycardia, fatigue, dizziness, weakness, chest discomfort, reduced exercise capacity, increased urination, shortness of breath, angina, presyncope, syncope, sleeping difficulties, confusion, and psychosocial distress, or any AF symptom described herein.
[0053] In some embodiments, the patient also exhibits diastolic dysfunction. Diastolic dysfunction may include, e.g., impaired left ventricle relaxation, filling, or diastolic distensibility, or left ventricle stiffness. In some embodiments, these traits may be measured using echocardiography. The diastolic dysfunction may be symptomatic or asymptomatic. [0054] Diastolic dysfunction is present or an important feature of a series of diseases including, but not limited to, hypertrophic cardiomyopathy (HCM), left ventricular hypetrophy (LVH) - including malignant LVH, heart failure with preserved ejection fraction (HFpEF) - including both disorders of active relaxation and disorders of chamber stiffness (diabetic HFpEF), dilated cardiomyopathy (DCM), ischemic cardiomyopathy, cardiac transplant allograft vasculopathy, restrictive cardiomyopathy - including inflammatory subgroups (e.g., Loefflers and EMF), infiltrative subgroups (e.g., amyloid, sarcoid and XRT), storage subgroups (e g., hemochromatosis, Fabry and glycogen storage disease), idiopathic/inherited subgroups such as Trop I (P-myosin HC), Trop T (a-cardiac actin) and desmin related (usually includes skeletal muscle), congenital heart disease subgroups (including pressure-overloaded RV, Tetrology of Fallot (diastolic dysfunction pre-op and early post-op, systolic dysfunction post-op) and pulmonic stenosis), and valvular heart disease (e.g., aortic stenosis- including elderly post AVR/TAVR and congenital forms).
[0055] In certain embodiments, the patient exhibiting atrial dysfunction also exhibits hypertrophic cardiomyopathy (HCM). Hypertrophic cardiomyopathy (HCM) is defined clinically as unexplained left ventricular (LV) hypertrophy in the absence of known causes such as pressure overload, systemic diseases, or infiltrative processes. The phenotypic hallmark of HCM is myocardial hypercontractility accompanied by reduced LV compliance, reflected clinically as reduced ventricular chamber size, often supranormal ejection fraction, increased wall thickness, and diastolic dysfunction. Some of the symptoms that HCM patients have include, but are not limited to, shortness of breath (especially during exercise), chest pain
(especially during exercise), fainting (especially during or just after exercise), sensation of rapid, fluttering or pounding heartbeats, and heart murmur.
[0056] In certain embodiments, HCM is obstructive HCM. It is generally understood that obstructive HCM (oHCM) is defined as at least a 30 mm Hg (i.e., 30 mm Hg or higher) pressure gradient across the LVOT in an individual at rest, during or immediately after Valsalva maneuver, or post-exercise. In some embodiments, an individual with oHCM has an LVOT pressure gradient of at least 35, 40 mm Hg, 45 mm Hg or 50 mm Hg. In some embodiments, the pressure gradient across the LVOT in the individual is measured at rest. In some embodiments, the pressure gradient across the LVOT in the individual is measured during or immediately after a Valsalva maneuver is performed. In some embodiments, the pressure gradient across the LVOT in the individual is measured post-exercise. oHCM may lead to severe symptoms of heart failure, arrhythmias, and/or death.
[0057] In certain embodiments, HCM is non-obstructive HCM.
[0058] In some embodiments, the patient additionally has one or more conditions selected from sleep apnea, hypertension, hyperlipidemia, hyperthyroidism, obesity, diabetes mellitus, glucose intolerance, alcohol use, tobacco use, prior myocardial infarction, chronic obstructive pulmonary disease, heart failure, coronary heart disease, rheumatic heart disease, valvular heart disease, nonvalvular heart disease, left ventricular hypertrophy, left ventricular diastolic dysfunction, and renal disease.
[0059] The therapies of the present disclosure may be used to treat a patient with AF with or without diastolic dysfunction (e.g., HCM). In some instances, the therapies may be used to maintain sinus rhythm (e.g., normal sinus rhythm) in a patient with AF, and/or may be used to reduce atrial fibrillation recurrence in a patient with AF.
[0060] A therapy described herein may include the step of selecting a patient with a type of atrial dysfunction as described herein (e.g., AF). In some embodiments, the patient is further selected as having a type of diastolic dysfunction as described herein (e.g., HCM).
[0061] In some embodiments, a patient treated by a therapy described herein has previously been or is being treated for the atrial dysfunction and/or diastolic dysfunction, with, for example, the standard of care for said condition(s), and has not shown adequate improvement with said treatment.
Treatment Regimens
[0062] The Compound I therapies described herein may treat atrial dysfunction (e.g., AF) in a patient. In certain embodiments, the patient may also have diastolic dysfunction such as HCM. The patient may receive a therapy of the present disclosure for at least one month, at least six months, at least twelve months, at least one year, or longer, or until such time the patient no longer needs the treatment.
[0063] In some embodiments of the present therapies, Compound I (e.g., mavacamten or Compound A) is administered in a total oral daily dosage of about 1 mg to 50 mg. In some embodiments, the total daily dosage is about 1 mg to 50 mg. In some embodiments, the total daily dosage of Compound I is about 2 mg to 30 mg, 10 mg to 20 mg, 2 mg to 10 mg, or 2 mg to 5 mg. In some embodiments, the total daily dosage of Compound I is 2.5 mg to 15 mg. In some embodiments, the total daily dosage of Compound I is 5 mg to 15 mg. In some embodiments, the total daily dosage of Compound I is 2 mg to 15 mg. In some embodiments, the total daily dosage of Compound I is 1 mg to 15 mg. In some embodiments, the effective amount to achieve and maintain the desired blood plasma concentration of Compound I is from 2.5 to 20 mg.
[0064] In some embodiments of the present therapies, Compound I (e.g., mavacamten or Compound A) is administered in a total oral daily dosage (e.g., once daily) of 1, 2, 2.5, 5, 7.5, 10, 15, 20, or 25 mg.
[0065] The dosage used for a particular patient may be adjusted based on the patient’s condition and/or the patient’s unique PK profile. In some embodiments, Compound I (e.g., mavacamten or Compound A) is dosed such that its plasma concentration in the subject is between 225-600 ng/mL, 350-700 ng/mL, or 150-600 ng/mL. In certain embodiments, Compound I is dosed such that its plasma concentration in the subject is between 200-400 ng/mL. The Compound I plasma concentration may be determined by any method known in the art, such as, for example, high performance liquid chromatography (HPLC), liquid chromatography-mass spectroscopy (LC-MS such as high performance LC-MS), gas chromatography (GC), or any combination thereof.
[0066] In some embodiments, Compound I is administered to the patient at a dose whereby the LVOT within the subject decreases without a significant change in LVEF.
[0067] As used herein, administration of Compound I or a pharmaceutical composition containing Compound I (“Compound I medication”) includes self-administration by the patient himself or herself (e.g., oral intake by the patient).
[0068] In particular embodiments, Compound I is mavacamten.
Combination Therapy
[0069] The present disclosure provides both Compound I monotherapy and combination therapy. In combination therapy, a Compound I regimen of the present disclosure is used in combination with an additional therapy regimen, e.g., a guideline-directed medical therapy (GDMT), also referred to as a standard of care (SOC) therapy, for one or more cardiac conditions exhibited by the patient, or other therapy useful for treating the relevant disease or disorder. The additional therapeutic agent may be administered by a route and in an amount commonly used for said agent or at a reduced amount, and may be administered simultaneously, sequentially, or concurrently with Compound I.
[0070] In some embodiments, Compound I is administered on top of the SOC for a condition of atrial dysfunction, such as atrial fibrillation; a condition of diastolic dysfunction, such as HCM; or both.
[0071] In certain embodiments, the patient exhibiting atrial dysfunction (e.g., atrial fibrillation) is given, in addition to the Compound I medication, another therapeutic agent for treating the atrial dysfunction. In some embodiments, the therapeutic agent is an antithrombotic agent (e.g., an anticoagulant such as a novel oral anticoagulant (NOAC)), a rate control agent, an anti arrhythmic agent (e.g., a Class la, Ic, or III anti arrhythmic agent), a pharmacological cardioversion agent, a RAAS inhibitor, etc. In some embodiments, the Compound I medication is administered to a patient who has had or plans to have a non-pharmacological intervention such as electrical cardioversion, left atrial appendage occlusion/excision, atrioventricular nodal ablation (e.g., with permanent ventricular pacing), AF catheter ablation, AF surgical ablation (e.g., Maze procedure), pulmonary vein ablation, or a permanent pacemaker. Any combination of the above agents and interventions is also contemplated.
[0072] In some embodiments, the Compound I medication is administered to the patient in place of an anti arrhythmic agent. The patient may have had prior treatment with an
anti arrhythmic agent that is then replaced by the Compound I medication, or the patient may be treated with the Compound I medication without prior treatment with an anti arrhythmic agent.
[0073] In some embodiments, a patient with atrial dysfunction (e.g., AF) is treated with a beta blocker in addition to the Compound I medication.
[0074] In some embodiments, a patient with atrial dysfunction (e.g., AF) is treated with an anticoagulant (e.g., a NOAC) in combination with a rate control agent (e.g., a beta blocker, digoxin, and/or amiodarone) in addition to the Compound I medication.
[0075] In some embodiments, a patient with atrial dysfunction (e.g., AF) is treated with an anticoagulant (e.g., a NOAC) in combination with a rate control agent (e.g., a beta blocker, digoxin, and/or amiodarone) in addition to the Compound I medication.
[0076] In some embodiments, a patient with atrial dysfunction (e.g., AF) is treated with cardioversion (e.g., electrical cardioversion) in addition to the Compound I medication.
[0077] In some embodiments, a patient with atrial dysfunction (e.g., AF) is treated with cardioversion (e.g., electrical cardioversion) in combination with an anti arrhythmic drug (e.g., amiodarone, sotalol, or dofetilide) in addition to the Compound I medication.
[0078] In certain embodiments, the patient exhibiting diastolic dysfunction (e.g., HCM) in addition to the atrial dysfunction (e.g., AF) is given, in addition to the Compound I medication and optionally a therapeutic agent for treating the atrial dysfunction as described herein, another therapeutic agent for treating the diastolic dysfunction. In some embodiments, the therapeutic agent is a beta blocker, a calcium channel blocker (e.g., a non-dihydropyridine calcium channel blocker), disopyramide, or any combination thereof. In certain embodiments, the beta blockers and/or calcium channel blockers are selected from those described herein, in any combination.
[0079] In some embodiments, a patient with atrial dysfunction (e.g., AF) and diastolic dysfunction (e.g., HCM) is treated with surgical myectomy in addition to Compound I medication.
[0080] In some embodiments, a patient with atrial dysfunction (e.g., AF) and diastolic dysfunction (e.g., HCM) is treated with alcohol septal ablation in addition to Compound I medication.
[0081] In some embodiments, a patient with atrial dysfunction (e.g., AF) and diastolic dysfunction (e.g., HCM) is treated with an anticoagulant (e.g., an oral anticoagulant (OAC)) in combination with an anti arrhythmic agent and/or AF catheter ablation in addition to the
Compound I medication.
[0082] In some embodiments, a patient with atrial dysfunction (e.g., AF) and diastolic dysfunction (e.g., HCM) is treated with amiodarone and/or disopyramide combined with a beta blocker and/or a nondihydropyridine calcium channel antagonist in addition to the Compound I medication.
[0083] In some embodiments, a patient with atrial dysfunction (e.g., AF) and diastolic dysfunction (e.g., HCM) is treated with sotalol, dofetilide, and/or dronedarone in addition to the Compound I medication.
[0084] In some embodiments, a patient with atrial dysfunction (e.g., AF) and diastolic dysfunction (e.g., HCM) is treated with an angiotensin receptor neprilysin inhibitor (ARNI) in addition to the Compound I medication. In certain embodiments, the patient is treated with sacubitril, valsartan, or Entresto® in addition to the Compound I medication.
[0085] In some embodiments, Compound I is administered to a patient with atrial dysfunction (e.g., AF) on top of the SOC for obstructive or non-obstructive HCM in combination with AF.
[0086] Suitable anti arrhythmic medications (rhythm control agents) may include, e.g., amiodarone, dronedarone, propafenone, flecainide, dofetilide, ibutilide, quinidine, procainamide, disopyramide, and sotalol. In some embodiments, the anti arrhythmic medications are of Class la, Ic, or III.
[0087] Suitable anticoagulants may include, e.g., warfarin, apixaban, rivaroxaban, edoxaban, and dabigatran. In some embodiments, the anticoagulants are oral anticoagulants (OACs); in certain embodiments, OACs may be administered with vitamin K antagonists. In some embodiments, the anticoagulants are non-vitamin K oral anticoagulants (NOACs).
[0088] Suitable pharmacological cardioversion agents include, e.g., flecainide, dofetilide, propafenone, ibutilide, vernakalant, etc.
[0089] Suitable rate control agents include, e.g., beta blockers, non-dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem), digitalis, and amiodarone. Suitable beta blockers include, e.g., bisoprolol, carvedilol, carvedilol CR, atenolol, esmolol, propranolol, nadolol, metaprolol tartrate, and metoprolol succinate extended release (metoprolol CR/XL)).
[0090] In some embodiments, Compound I is administered in combination with lifestyle changes such as reducing alcohol or caffeine intake, quitting smoking, limiting stimulants,
achieving or maintaining a healthy weight, physical activity, treating sleep apnea, and/or controlling high blood pressure and/or blood sugar levels, or any combination thereof.
[0091] If any adverse effect occurs, the patient may be treated for the adverse effect. For example, a patient experiencing headache due to the Compound I treatment may be treated with an analgesic such as ibuprofen and acetaminophen.
[0092] Any combination of the above agents and treatments is also contemplated for treating a patient in combination with the Compound I medication.
Treatment Outcomes
[0093] The therapies of the present disclosure treat and/or ameliorate atrial dysfunction. In some embodiments, the therapies also treat and/or ameliorate diastolic dysfunction. As used herein, the terms “treat,” “treating” and “treatment” refer to any indicia of success in the treatment or amelioration of a pathology, injury, condition, or symptom related to the dysfunction, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms; making the pathology, injury, condition, or symptom more tolerable to the patient; decreasing the frequency or duration of the pathology, injury, condition, or symptom; or, in some situations, delaying or preventing the onset of the pathology, injury, condition, or symptom. Treatment or amelioration can be based on any objective or subjective parameter, including, e.g., the result of a physical examination.
[0094] For example, treatment of atrial dysfunction (e.g., AF) encompasses, but is not limited to, any one or combination of: improving atrial myocyte contractility, improving atrial contractility, improving atrial cardiomyopathy, improving atrial arrhythmia (e.g., tachyarrhythmia), reducing AF recurrence, reducing AF burden, preventing incident AF, maintaining sinus rhythm (e.g., after cardioversion), restoring sinus rhythm (e.g., in combination with cardioversion), decreasing left atrial volume, increasing left atrial emptying fraction, increasing left atrial function index, preventing conversion of a-MHC to 0-MHC in the LA, and alleviating or preventing the symptoms of atrial dysfunction. Symptoms of atrial dysfunction (e.g., AF) may include, e.g., heart palpitations, tachycardia, fatigue, dizziness, weakness, chest
discomfort, reduced exercise capacity, increased urination, shortness of breath, angina, presyncope, syncope, sleeping difficulties, confusion, and psychosocial distress.
[0095] Treatment of diastolic dysfunction encompasses, but is not limited to, any one or combination of improving the cardiac functions of the patient and alleviating or preventing the symptoms of diastolic dysfunction (especially during exercise, including walking or stair climbing). Symptoms of diastolic dysfunction such as HCM may include, e.g., shortness of breath (especially during exercise), chest pain (especially during exercise), fainting (especially during or just after exercise), sensation of rapid, fluttering or pounding heartbeats, atrial and ventricular arrhythmias, heart murmur, hypertrophied and non-dilated left ventricle, thickened heart muscle, thickened left ventricular wall, elevated pressure gradient across left ventricular outflow tract (LVOT), elevated post-exercise LVOT gradient, and high left ventricular ejection fraction (LVEF).
[0096] In some embodiments, the therapies of the present disclosure reduce AF burden and/or AF recurrence in a patient (e.g., a patient from a population described herein). AF burden and/or AF recurrence may be reduced by 10% or greater. In some embodiments, AF burden and/or AF recurrence are reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or greater, or 100%. In some embodiments, the percentage of time the patient spends in AF during a monitoring period is reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or greater, or 100%. In some embodiments, the therapies reduce the duration of a patient’s longest AF episode, or the number of AF episodes during a monitoring period, e.g., by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% or greater, or 100%. In some embodiments, the monitoring period may be 24 hours, 1 week, 2 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, or more. [0097] In some embodiments, the therapies of the present disclosure maintain sinus rhythm (e.g., normal sinus rhythm) in a patient (e.g., a patient from a population described herein). In certain embodiments, the patient has been treated with or will be treated with cardioversion (e.g., electrical cardioversion). In some embodiments, the therapies of the present disclosure, in combination with cardioversion (e.g., electrical cardioversion), restore sinus rhythm (e.g., normal sinus rhythm) in a patient. In some embodiments, sinus rhythm is maintained for at least one, two, three, four, five, six, or seven days; at least one, two, three, or four weeks; at least one, two,
three, four, five, six, nine, or twelve months; at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 years; or longer; or until such time that the patient no longer needs the treatment.
[0098] In some embodiments, the therapies of the present disclosure reduce the risk of, or delay the incidence of, myocardial infarction, ventricular arrhythmia, heart failure, chronic kidney disease, end-stage renal disease, sudden cardiac death, or all-cause death in a patient. [0099] In some embodiments, the therapies of the present disclosure improve the patient’s quality of life, as measured by the 6-Month Walk Test (6-MWT), Kansas City Cardiomyopathy Questionnaire (KCCQ), Atrial Fibrillation Effect on Quality-of-Life (AFEQT) measure, and/or Mayo AF-Specific Symptom Inventory (MAFSI).
[0100] In some embodiments, the therapies of the present disclosure prevent or delay tachycardia-induced cardiomyopathy in patients exhibiting atrial fibrillation.
[0101] In some embodiments, the therapies of the present disclosure prevent or delay incident AF (initial occurrence of AF) in patients. Additionally or alternatively, the therapies may prevent or delay AF recurrence in patients.
[0102] Pharmacodynamic (PD) parameters that can be used to measure the atrial functions of a patient are shown in Table 3 below. These PD parameters are routinely used by clinicians and can be measured by standard transthoracic echocardiogram.
[0103] In some embodiments, the therapies of the present disclosure:
- increase LAEF in the patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more;
- decrease LAminVi in the patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more;
- decrease LAmaxVi in the patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more; and/or
- increase LAFI in the patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, or more.
[0104] In some embodiments, the therapies of the present disclosure reduce biomechanical remodeling of the left atrium, such as increased maximal force and slowed cross-bridge formation rates (e.g., in a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM).
[0105] In some embodiments, the therapies of the present disclosure prevent, slow, and/or reverse the conversion of a-myosin heavy chain (MHC) to p-MHC in the left atrium of a patient by 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more (e.g., in a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM).
[0106] In some embodiments, the therapies of the present disclosure
- reduce cardiac troponin T (cTnT leakage) by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more; and/or
- reduce incidence of cTNT by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, or more (e.g., in a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM).
In certain embodiments, the cTnT is high sensitivity cTnT.
[0107] In some embodiments, the therapies of the present disclosure downregulate BNP and/or pro-fibrotic genes (e.g., SPP1, NPPB, TGF-01, TGF-P2, FN1, CCN2, or any combination thereof) by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more.
[0108] In some embodiments, the therapies of the present disclosure reduce mortality in a patient by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or more (e.g., in a patient with atrial dysfunction such as AF and/or diastolic dysfunction such as HCM).
[0109] The patient treated with a therapy described herein may exhibit New York Heart Association (NYHA) Class I, II, III, or IV heart failure, as defined in Table 2 below. In certain embodiments, the patient has NYHA Class II- IV heart failure. In some embodiments, the therapies of the present disclosure improve, stabilize, or delay worsening of the NYHA functional classification of the patient.
Table 2. New York Heart Association (NYHA) Classes of Heart Failure
[0110] The present therapies may reduce the risk of cardiovascular death, and/or the risk, frequency, or duration of hospitalization/urgent care visits, for a patient population described herein. The hospitalization and urgent care visits may be for atrial dysfunction as described herein, diastolic dysfunction as described herein, or both. In some embodiments, “reducing the risk” of an event means increasing the time to the event by at least 10% (e.g., at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more). The risk can be relative risk or absolute risk. In some embodiments, the present therapies reduce the frequency of hospitalization and urgent care visits by at least 10% (e.g., at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%). In some embodiments, the present therapies reduce the duration of hospitalization by at least 10% (e.g., at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%).
Articles of Manufacture and Kits
[OHl] The present invention also provides articles of manufacture, e.g., kits, comprising one or more dosages of the Compound I medication, and instructions for patients (e.g., for treatment in accordance with a method described herein). The articles of manufacture may also contain an additional therapeutic agent in the case of combination therapy. Compound I tablets or capsules may be blistered and then carded, produced with, for example, 5-20 tablets per blister card; each tablet or capsule may contain 1, 2, 2.5, 5, 7.5, 10, 15, 20, or 25 mg of Compound I, and such blister card may or may not additionally include a loading dose tablet or capsule. The present disclosure also includes methods for manufacturing said articles.
[0112] Unless otherwise defined herein, scientific and technical terms used in connection with the present disclosure shall have the meanings that are commonly understood by those of ordinary skill in the art. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure. In case of conflict, the present specification, including definitions, will control. Generally, nomenclature used in connection with, and techniques of, cardiology, medicine, medicinal and pharmaceutical chemistry, and cell biology described herein are those well-known and commonly used in the art. Enzymatic reactions and purification techniques are performed according to manufacturer’s specifications, as commonly accomplished in the art or as described herein. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Throughout this specification and embodiments, the words “have” and “comprise,” or variations such as “has,” “having,” “comprises,” or “comprising,” will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. As used herein the term “about” refers to a numerical range that is 10%, 5%, or 1% plus or minus from a stated numerical value within the context of the particular usage. Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed embodiments.
[0113] All publications and other references mentioned herein are incorporated by reference in their entirety. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art.
[0114] In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only and are not to be construed as limiting the scope of the invention in any manner.
EXAMPLES
Example 1: Chronic Treatment with Compound A in a Mini-Pig Model of Inherited
Hypertrophic Cardiomyopathy
[0115] This Example describes an in vivo study that evaluates the chronic effects of Compound
A, in a genetic large-animal model of HCM.
Materials and Methods
[0116] Young (~1 month) cloned Yucatan mini-pigs with a heterozygous MYH7 R403Q mutation (“HCM pigs”) were treated and evaluated as shown in FIG. 1. The pigs were randomly assigned to one of two arms: untreated controls (CTRL, n = 29) or daily Compound A (n = 22; PO); untreated wild-type pigs (WT) served as disease controls. The pigs treated with Compound A were divided into two cohorts: A and B. Treated animals received progressively increasing Compound A doses (5, 7.5, 10, and 15 mg/day PO) to account for weight gain. After 14 weeks of treatment, pigs underwent in vivo cardiac MRI (cMR) imaging, including T1 mapping and extracellular volume (ECV) assessments. In a subset of pigs (Cohort B), biomechanical studies were performed in skinned left-ventricular (LV) and left-atrial (LV) fibers.
Results
[0117] In HCM pigs, Compound A treatment decreased mortality (9.0* vs. 37.9% in CTRL, p < 0.05). Compound A blunted cTnT leakage, reducing both absolute values (21.2 ± 3.2* vs. 34.0 ± 4.3 ng/L in CTRL) and the incidence of cTnT > 20 ng/L (36* vs. 81% in CTRL). Moreover, Compound A caused downregulation of BNP and pro-fibrotic genes (e.g., NPPB, TGF-01 and 02, SPP1, FN1, and CCN2) that were elevated in the CTRL group (FIG. 2). Treated pigs had smaller LA volumes (16 ± 1* vs. 29 ± 4mL in CTRL) with lower LV Tl-times and ECV (27 ± 1* vs. 32 ± 2% in CTRL). LA fibers from untreated HCM pigs showed biomechanical remodeling characteristic of chronic overload: increased maximal force (21.8 ± 1.5# vs. 14.7 ± 1.4 mN/mm2 in WT) and slowed cross-bridge formation rates (Ktr: 4.9 ± 0.4 # vs. 6.6 ± 0.6 s-1 in WT) consistent with a switch towards slow-myosin isoforms. Compound A prevented this remodeling (e.g., Ktr: 8.1 ± 1.3 s-1*), preserving normal LA (fast) myosin content and isometric tension redevelopment dynamics (FIG. 3). *, #: P<0.05 vs. CTRL or WT.
[0118] As demonstrated by the above data, chronic direct myosin attenuation with Compound A prevented left atrial remodeling, a known prognostic indicator in HCM. Chronic treatment also reduced cardiac troponin leakage characteristic of HCM, and decreased mortality. Taken together, these observations show potential salutary effects beyond obstruction relief in HCM.
Example 2: Biochemical Properties of Compound A and Mavacamten
[0119] This Example describes a study that demonstrates that Compound A mirrors the
functional properties of mavacamten.
[0120] Mavacamten is a cardiac-specific, small-molecule allosteric modulator of B-cardiac myosin that reversibly inhibits its binding to actin. Compound A is a mavacamten surrogate in which a hydrogen has been substituted with fluorine. To compare the activity of Compound A and mavacamten, both compounds were tested in bovine cardiac myofibrils for inhibition of myosin ATPase. At pCa 6.0, Compound A and mavacamten exhibited similar inhibition of myosin ATPase activity over the tested concentration range (FIG. 4). Comparative studies of Compound A and mavacamten in bovine cardiac synthetic myosin filaments showed similar disordered relaxed state (DRX) and super-relaxed state (SRX) ATPase rates (as a fraction of control) for the two compounds over a range of concentrations (FIG. 5). Due to the abovedescribed similarities, mavacamten is expected to perform similarly to Compound A in the treatments described herein.
Claims
1. A method of treating atrial dysfunction in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the patient exhibits atrial fibrillation.
2. A method of treating atrial cardiomyopathy in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the patient exhibits atrial fibrillation.
3. A method of treating atrial tachyarrhythmia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the patient exhibits atrial fibrillation.
4. A method of treating atrial fibrillation in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine.
5. A method of reducing atrial fibrillation recurrence in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein atrial fibrillation recurrence is reduced by 10% or greater.
6. A method of reducing atrial fibrillation burden in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein atrial fibrillation burden is reduced by 10% or greater.
7. A method of reducing the duration of an atrial fibrillation episode in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the duration of the episode is reduced by 10% or greater.
8. A method of reducing the number of atrial fibrillation episodes during a monitoring period in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the number of atrial fibrillation episodes is reduced by 10% or greater.
9. A method of maintaining sinus rhythm in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the patient has sustained atrial tachyarrhythmia for 12 months or less prior to the administering step, further optionally wherein the atrial tachyarrhythmia is atrial fibrillation.
10. A method of restoring sinus rhythm in a patient exhibiting atrial tachyarrhythmia, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the cardioversion is electrical cardioversion and further optionally wherein the atrial tachyarrhythmia is atrial fibrillation.
11. A method of preventing or slowing the conversion of a-myosin heavy chain (MHC) to P-
MHC in the left atrium of a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the patient exhibits atrial fibrillation.
12. A method of reversing the conversion of a-myosin heavy chain (MHC) to 0-MHC in the left atrium of a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, further optionally wherein the patient exhibits atrial fibrillation.
13. The method of any one of claims 1-12, wherein n is 0.
14. The method of any one of claims 1-12, wherein R is fluorine.
15. The method of claim 14, wherein n is 1.
16. The method of claim 15, wherein R is a fluorine at position 3.
17. The method of any one of claims 1-16, wherein the patient also exhibits diastolic dysfunction.
18. The method of claim 17, wherein the diastolic dysfunction is hypertrophic cardiomyopathy (HCM).
19. The method of claim 18, wherein the hypertrophic cardiomyopathy is obstructive hypertrophic cardiomyopathy (oHCM).
20. The method of claim 19, wherein the patient has at least a 30 mm Hg pressure gradient across the left ventricular outflow tract (LVOT) at rest, during or immediately after a Valsalva maneuver, or post-exercise.
21. The method of claim 18, wherein the hypertrophic cardiomyopathy is non-obstructive hypertrophic cardiomyopathy (nHCM).
22. The method of any one of claims 1-21, wherein the patient has heart failure and a diagnosis of any one of NYHA Class II-IV.
23. The method of any one of claims 1-22, wherein the patient exhibits atrial fibrillation; and the therapeutically effective amount of Compound I alleviates one or more symptoms of HCM, maintains sinus rhythm, reduces atrial fibrillation recurrence, and/or prevents incident atrial fibrillation in the patient.
24. A method of preventing tachycardia-induced cardiomyopathy in a patient exhibiting atrial fibrillation, comprising administering to the patient a therapeutically effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine.
25. The method of any one of claims 1-24 wherein the patient has sustained the tachyarrhythmia or atrial fibrillation for a duration of 12 months or less prior to the administering step.
26. The method of any one of claims 1-25, wherein the patient has an atrial fibrillation burden of 2-70%.
27. The method of any one of claims 1-26, wherein the Compound I is administered to the patient orally.
28. The method of any one of claims 1-27, wherein the patient has undergone an electrical cardioversion before or after the administering step, optionally where the electrical cardioversion is performed no more than 24 hours before or after the administering step.
29. The method of any one of claims 1-28, further comprising administering to the patient an additional medication for improving cardiovascular conditions in the patient.
30. The method of any one of claims 1-29, wherein the method results in any one or combination of the following: a) reduced risk of urgent outpatient intervention for atrial dysfunction, diastolic dysfunction, or both; b) improved quality of life as measured through 6-MWT or KCCQ; c) improved exercise capacity; d) improvement in a patient’ s NYHA classification; e) delay in clinical worsening; f) reduction in severity of cardiovascular-related symptoms; g) increased left atrial ejection fraction (LAEF); h) decreased left atrial volume (LAminVI); i) improved left atrial function index (LAFI); j) reduced cTnT leakage; k) decreased BNP; and l) decreased expression of pro-fibrotic genes.
31. The method of any one of claims 1-30, wherein the method results in reduced cardiovascular death or hospitalization.
32. The method of any one of claims 1-30, wherein the method results in reduced stroke, embolism, or heart failure.
33. A compound of formula (I)
or a pharmaceutically acceptable salt thereof, wherein n is 0, 1, 2, 3, 4, or 5, and R is a halogen, optionally a fluorine, or a pharmaceutical composition comprising the compound and a pharmaceutically acceptable excipient, for use in treating a disease according to any one of claims 1-32.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263381966P | 2022-11-02 | 2022-11-02 | |
US63/381,966 | 2022-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024097284A1 true WO2024097284A1 (en) | 2024-05-10 |
Family
ID=89073294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/036587 WO2024097284A1 (en) | 2022-11-02 | 2023-11-01 | Mavacamten and derivatives thereof for use in treating atrial dysfunction |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024097284A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019028360A1 (en) * | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
WO2021092598A1 (en) * | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
-
2023
- 2023-11-01 WO PCT/US2023/036587 patent/WO2024097284A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019028360A1 (en) * | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
WO2021092598A1 (en) * | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
Non-Patent Citations (15)
Title |
---|
ABELLA LINA MARIA RAYO ET AL: "Effects of omecamtiv mecarbil and mavacamten in isolated human atrium", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 396, no. 3, 18 November 2022 (2022-11-18), DE, pages 499 - 511, XP093118648, ISSN: 0028-1298, Retrieved from the Internet <URL:https://link.springer.com/article/10.1007/s00210-022-02333-0/fulltext.html> DOI: 10.1007/s00210-022-02333-0 * |
BARTH ET AL., CIRCULATION RESEARCH, vol. 96, no. 9, 2005, pages 1022 - 9 |
BELL ET AL: "Abstract 17492: Chronic Treatment With a Mavacamten-Like Myosin-Modulator (MYK-581) Prevents Left-Atrial Remodeling, Decreases Cardiac Troponin Leakage, and Blunts Mortality in a Mini-Pig Model of Inherited Hypertrophic Cardiomyopathy | Circulation", CIRCULATION, 12 November 2020 (2020-11-12), pages 1 - 6, XP093119159, Retrieved from the Internet <URL:https://www.ahajournals.org/doi/10.1161/circ.142.suppl_3.17492> [retrieved on 20240112] * |
BELUS ET AL., CIRCULATION RESEARCH, vol. 107, no. 1, 2010, pages 144 - 52 |
EIRAS ET AL., JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 41, 2006, pages 467 - 77 |
HIROSE ET AL., EUR HEART J., vol. 13, no. 3, 2012, pages 243 - 50 |
ISMAYL MAHMOUD ET AL: "Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", CURRENT PROBLEMS IN CARDIOLOGY, vol. 48, no. 1, 1 January 2023 (2023-01-01), AMSTERDAM, NL, pages 101429, XP093118628, ISSN: 0146-2806, DOI: 10.1016/j.cpcardiol.2022.101429 * |
JANUARY ET AL., JACC, vol. 64, no. 21, 2014, pages 2246 - 80 |
KIRCHHOF ET AL., EUR HEART J., vol. 37, 2016, pages 2893 - 2962 |
NAG SUMAN ET AL: "Mavacamten, a precision medicine for hypertrophic cardiomyopathy: From a motor protein to patients", SCIENCE ADVANCES, vol. 9, no. 30, 28 July 2023 (2023-07-28), US, XP093101273, ISSN: 2375-2548, DOI: 10.1126/sciadv.abo7622 * |
NAROLSKA ET AL., JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, vol. 26, 2005, pages 39 - 48 |
SARDANA ET AL., JAM SOC ECHOCARDIOGR., vol. 30, no. 9, 2017, pages 904 - 12 |
SCHAAF ET AL., EUR HEART J CARDIOVASC IMAGING, vol. 18, 2017, pages 46 - 53 |
TOWER-RADER ALBREE ET AL: "Mavacamten: a novel small molecule modulator of [beta]-cardiac myosin for treatment of hypertrophic cardiomyopathy", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 29, no. 11, 20 September 2020 (2020-09-20), UK, pages 1171 - 1178, XP093118644, ISSN: 1354-3784, DOI: 10.1080/13543784.2020.1821361 * |
VON JEINSEN ET AL., JAM SOC ECHOCARDIOGRAPH, vol. 33, no. 1, 2019, pages 72 - 81 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI519298B (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality | |
ES2241305T3 (en) | COMBINATIONS AGAINST DIABETES CONTAINING GLIBURIDE, TROGLITAZONA (AND A BIGUANIDA). | |
Aronow | Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure | |
JP7494277B2 (en) | Methods of Treating Heart Failure With Reduced Ejection Fraction With Dapagliflozin | |
Kayano et al. | Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients―A Randomized Controlled Trial― | |
CA2727326A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
US20110124724A1 (en) | Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potasium level in the blood | |
TW202320763A (en) | Methods for treating hypertrophic cardiomyopathy | |
CN116056703A (en) | Treatment of atrial dysfunction | |
WO2024097284A1 (en) | Mavacamten and derivatives thereof for use in treating atrial dysfunction | |
JP2011517694A (en) | Combination of dronedarone and at least one diuretic and its therapeutic use | |
EP2386300A1 (en) | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality in patients having a first recurrence of atrial fibrillation or atrial flutter | |
US20240091203A1 (en) | Methods for treating non-obstructive hypertrophic cardiomyopathy | |
WO2012020377A1 (en) | Use of dronedarone for the preparation of a medicament for rhythm- and rate-controlling in patients with atrial fibrillation | |
US20080070917A1 (en) | Methods for administering levosimendan | |
Macovei et al. | Management of a rare case of adrenergic myocarditis complicated with cardiogenic shock | |
Kistler et al. | Management of atrial fibrillation | |
Choo et al. | Amiodarone rescue therapy for severe decompensated Heart failure initially unsuitable for β-blockers | |
TW201529068A (en) | Use of DRONEDARONE for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality | |
EA042257B1 (en) | METHODS FOR THE TREATMENT OF HEART FAILURE WITH REDUCED EJECTION FRACTION USING DAPAGLIFLOSIN | |
Golledge et al. | Current management of hypertrophic cardiomyopathy | |
Munger et al. | Invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for heart failure | |
BARKLEY JR | I. Definition/general comments | |
Habersberger et al. | Management of atrial fibrillation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23817594 Country of ref document: EP Kind code of ref document: A1 |